



## SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 \*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6600)

# POLL RESULTS OF THE ANNUAL GENERAL MEETING AND CHANGE OF NON-EXECUTIVE DIRECTOR

At the annual general meeting (the “AGM”) of SciClone Pharmaceuticals (Holdings) Limited (the “Company”) held on Wednesday, June 16, 2021, all the proposed resolutions as set out in the notice of the AGM dated May 14, 2021 were taken by poll.

## Poll Results of the AGM

The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements and the reports of the directors and auditors for the year ended December 31, 2020.	491,568,200 (100%)	0 (0%)
2(a).	To re-elect Mr. Zhao Hong as an executive director of the Company.	491,148,200 (99.91%)	420,000 (0.09%)
2(b).	To re-elect Mr. Li Zhenfu as a non-executive director of the Company.	491,395,700 (99.96%)	172,500 (0.04%)
2(c).	To re-elect Dr. Daniel Luzius Vasella as a non-executive director of the Company.	491,395,700 (99.96%)	172,500 (0.04%)
2(d).	To re-elect Ms. Lin Shirley Yi-Hsien as a non-executive director of the Company.	491,395,700 (99.96%)	172,500 (0.04%)
2(e).	To re-elect Ms. Li Quan as a non-executive director of the Company.	491,395,700 (99.96%)	172,500 (0.04%)
2(f).	To re-elect Mr. Shi Cen as a non-executive director of the Company.	491,395,700 (99.96%)	172,500 (0.04%)
2(g).	To elect Ms. Wang Haixia as a non-executive director of the Company.	491,395,700 (99.96%)	172,500 (0.04%)
2(h).	To re-elect Dr. Liu Guoen as an independent non-executive director of the Company.	491,568,200 (100%)	0 (0%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2(i).	To re-elect Dr. Chen Ping as an independent non-executive director of the Company.	491,568,200 (100%)	0 (0%)
2(j).	To re-elect Mr. Gu Alex Yushao as an independent non-executive director of the Company.	491,568,200 (100%)	0 (0%)
2(k).	To re-elect Ms. Wendy Hayes as an independent non-executive director of the Company.	491,568,200 (100%)	0 (0%)
2(l).	To authorize the board of directors to fix the respective directors' remuneration.	491,568,200 (100%)	0 (0%)
3.	To re-appoint PricewaterhouseCoopers as auditors and to authorize the board of directors to fix their remuneration.	491,568,200 (100%)	0 (0%)
4.	To give a general mandate to the directors to repurchase shares of the Company not exceeding 10% of total number of issued shares of the Company as at the date of passing of this resolution.	491,568,200 (100%)	0 (0%)
5.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	490,782,200 (99.84%)	786,000 (0.16%)
6.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	490,954,700 (99.88%)	613,500 (0.12%)

*Notes:*

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 6, all resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the AGM, the total number of shares of the Company in issue was 677,874,263 shares.
- (c) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 677,874,263 shares.
- (d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (e) No shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (f) None of the shareholders of the Company have stated their intention in the Company's circular dated May 14, 2021 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company's branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

## Change of Non-executive Director

As resolution No. 2(g) set above was duly passed by the shareholders at the AGM, Ms. Wang Haixia has been appointed as a non-executive director of the Company with effect from the conclusion of the AGM. For the biographical details of Ms. Wang Haixia, please refer to the circular of the Company dated May 14, 2021 (the “**Circular**”).

The board of directors (the “**Board**”) of the Company would like to take this opportunity to express its warmest welcome to Ms. Wang Haixia in joining the Board.

Reference is made to the Circular, as Ms. Wang Xiaozhuo decided not to offer herself for re-election due to her busy business schedule that makes it challenging for her to devote sufficient time to the Board, Ms. Wang Xiaozhuo ceased to be a non-executive director with effect from the conclusion of the AGM. Ms. Wang Xiaozhuo has confirmed that there is no disagreement between herself and the Board during her term of office and there is no matter relating to her retirement that needs to be brought to the attention of the shareholders.

The Board wishes to express its appreciation for the valuable contributions made by Ms. Wang Xiaozhuo towards the development of the Company during her term of office.

By order of the Board  
**SciClone Pharmaceuticals (Holdings) Limited**  
**ZHAO Hong**  
*Executive Director, Chief Executive Officer and President*

Hong Kong, June 16, 2021

*As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.*

\* *For identification purpose only*